The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.

@article{Tulloch1992ThePP,
  title={The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.},
  author={Ian F. Tulloch and A. M. Johnson},
  journal={The Journal of clinical psychiatry},
  year={1992},
  volume={53 Suppl},
  pages={
          7-12
        }
}
Paroxetine is a highly potent and selective inhibitor of serotonin reuptake, being more potent in vitro than fluoxetine, fluvoxamine, and sertraline. In contrast to the tricyclic antidepressants, paroxetine has little affinity for catecholaminergic or histaminergic systems. Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable. Unlike the metabolites of fluoxetine and sertraline, the metabolites of paroxetine are… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Treating Chronic Pain with SSRIs: What Do We Know?

  • Pain research & management
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Paroxetine hydrochloride.

  • Profiles of drug substances, excipients, and related methodology
  • 2013